Vivos (VVOS) files NT 10‑Q; expects >50% revenue jump, higher loss

Vivos Therapeutics (VVOS) filed a late notice for its Q3 2025 Form 10‑Q, citing the need for additional time to review and consolidate interim financial statements from its newly acquired subsidiary, The Sleep Center of Nevada (SCN), acquired on June 10, 2025.

Rhea-AI Filing Summary

Vivos Therapeutics (VVOS) filed a late notice for its Q3 2025 Form 10‑Q, citing the need for additional time to review and consolidate interim financial statements from its newly acquired subsidiary, The Sleep Center of Nevada (SCN), acquired on June 10, 2025. The company expects to file within the five‑day extension permitted under Rule 12b‑25.

Vivos anticipates that revenue increased by over 50% for the three months ended September 30, 2025 versus the prior‑year period, driven primarily by higher sales of Vivos products and services originating from SCN. The company also expects Sales, General and Administrative expenses to rise by over 50%, reflecting salaries, rent and other SCN operating costs, and therefore anticipates a higher net loss year over year. These figures remain under review and may change when the Form 10‑Q is filed.

Insights

Equity analyst

Late 10‑Q tied to acquisition integration; prelims show >50% revenue growth but higher loss.

Vivos Therapeutics indicates its Q3 Form 10‑Q will be delayed due to consolidating SCN’s interim financials after the June 10, 2025 acquisition. This is an administrative step under Rule 12b‑25 with an allowed five‑day extension.

The company preliminarily sees >50% year‑over‑year revenue growth for the quarter ended September 30, 2025, largely from SCN. However, SG&A is also expected to rise by >50% from added salaries, rent, and operating costs, leading to a larger net loss.

Actual impact depends on final consolidated results and expense trajectory post‑integration. Subsequent filings will provide the definitive revenue, expense, and net loss figures once the 10‑Q is submitted.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vivos Therapeutics (VVOS) file and why?

Vivos filed an NT 10‑Q to notify a late Q3 2025 report due to extra time needed to review and consolidate SCN’s interim financials.

When does VVOS expect to file its Q3 2025 Form 10‑Q?

The company expects to file within the five‑day extension allowed under Rule 12b‑25.

What acquisition is affecting VVOS’s reporting?

Vivos acquired The Sleep Center of Nevada (SCN) on June 10, 2025, and is consolidating SCN’s interim financial statements.

How is VVOS’s Q3 2025 revenue expected to change?

The company anticipates revenue increased by over 50% year over year, primarily from SCN‑related product and service sales.

What is the expected change in VVOS’s SG&A expenses?

SG&A expenses are anticipated to rise by over 50%, reflecting salaries, rent, and other costs associated with SCN’s operations.

What is the expected impact on VVOS’s net loss?

Vivos anticipates an increase in net loss for Q3 2025 compared with Q3 2024.

Are these VVOS figures final?

No. The figures are still under review and may differ once the Form 10‑Q is filed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 04:01 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: September 30, 2025

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended: _____________________________________

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Full Name of Registrant	Vivos Therapeutics, Inc.
Former Name if Applicable	N/A
Address of Principal Executive Office (Street and Number)	7921 Southpark Plaza, Suite 210
City, State and Zip Code	Littleton, CO 80120

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Vivos Therapeutics, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) within the prescribed time period. On June 10, 2025, the Company acquired Prabhu-Lata K. Shete MDs, LTD., a Nevada professional corporation d/b/a The Sleep Center of Nevada (“SCN”). As of the date hereof, the Company and its independent registered public accounting firm requires additional time to complete the review of SCN’s interim financial statements and to consolidate such financial statements into the Company’s unaudited financial statements for the quarter ended September 30, 2025.

The Company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. 

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

R. Kirk Huntsman		(866) 908-4867
(Name)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☒ Yes ☐ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Company anticipates that its revenue increased by over 50% for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The primary cause was due to an increase in sales of Vivos products and services that originated from the Company’s newly acquired subsidiary SCN. 

The Company also anticipates that its Sales, General and Administrative expenses also increased by over 50% for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024. The primary cause of this increase was due to increase of salaries and wages, rent and other expenses associated with SCN’s operations. As a result, the Company anticipates an increase in its net loss for the three months ended September 30, 2025 as compared to the three months ended September 30, 2024.

The figures reported above are still under review and may differ once reported in the Form 10-Q to be filed by the Registrant.

Vivos Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2025	By:	/s/Bradford Amman
		Bradford Amman
		Chief Financial Officer